



# 2025 APPHON/ROHPPA Conference Program

May 1 to 3

1/5980 University Ave, Halifax NS | Virtual via MS Teams

---

## Speakers – Topics – Learning Objectives

---

### Thursday, May 1

#### Dr. Lisa Goodyear

##### **Hem/Onc Case Review**

At the conclusion of this activity, participants will be able to:

1. Interpret common and uncommon pediatric hematology bloodwork findings by applying clinical reasoning to real-world case scenarios. (medical expert, scholar)
2. Develop a systematic approach to generating a differential diagnosis based on abnormal bloodwork results and identifying key next steps in the diagnostic work-up. (medical expert, scholar, communicator)
3. Formulate appropriate management plans for pediatric patients based on bloodwork findings, incorporating evidence-based decision-making and multidisciplinary collaboration. (medical expert, collaborator, leader)

#### Jill Mitchell & Chantale Deyoung

##### **Chronic Transfusion Therapy**

At the conclusion of this activity, participants will be able to:

1. Recognize the purpose and benefits of chronic transfusion therapy.
2. Identify potential risks and complications.
3. Explain the process of chronic transfusion therapy.

#### Dr. Valerie Bourque-Riel

##### **Non-Malignant Neutropenias**

At the conclusion of this activity, participants will be able to:

1. Identify the treatment differences in non-malignant versus malignant neutropenias.
2. Review and assess the new non-malignant pathway for discussion and approval.

#### Dr. Lisa Pinto

##### **Iron in the community**

At the conclusion of this activity, participants will be able to:

1. Describe an approach to management of iron deficiency and iron deficiency anemia.
2. Identify indications for use of intravenous iron infusions.
3. Describe risks and benefits associated with intravenous iron infusions.

4. Describe an approach to management of iron deficiency anemia with intravenous iron when indicated.

### Friday, May 2

#### Mary Stuart

##### **Cardio Oncology**

At the conclusion of this activity, participants will be able to:

1. Discuss the development of Canadian and an international collaboration in cardiology and oncology, current nursing involvement, and current research ongoing.
2. Provide an overview of anthracyclines, targeted therapy and radiation and impact on pediatric cancer patients. Evaluate research on co-morbidities impacting pediatric patients pre and post treatment.
3. Identify what health care providers can do to change this trajectory. Assess recent research in nutrition and exercise as potential areas of focus as clinicians.
4. Define the current recommendations on cardiac surveillance and imaging from recent ASE 2024 guidelines.
5. Demonstrate a knowledge of resources.

#### Amanda Porter

##### **When a child or parent says 'no' to treatment**

At the conclusion of this activity, participants will be able to:

1. Identify some of the ethical challenges that surround a declining of treatment by a patient of their substitute decision maker.
2. Demonstrate an ability to have informed discussions of these kinds of cases.

#### Dr. Lillian Sung, Guest Speaker

##### **SSPedi: Symptom Screening in Pediatrics Tool**

At the conclusion of this activity, participants will be able to:

1. Identify the importance of symptoms in pediatric patients with cancer.
2. Explain the results of recent trials evaluating routine symptom screening in pediatric patients with cancer.
3. Recognize approaches to manage symptoms identified through symptom screening.

#### Dr. Chelsea Ash

##### **Precision Medicine in Pediatric Oncology: Expanding the Playing Field, or a Whole New Game?**

At the conclusion of this activity, participants will be able to:

1. Recognize the historical evolution of precision cancer medicines including that of prominent precision therapies in pediatric oncology. (medical expert, scholar)
2. Identify how targeted agents might complement, and potentially replace, conventional treatment approaches. (medical expert, collaborator)

3. Identify barriers to the development and clinical use of precision therapies in the pediatric population. (health advocate)

**Dr. Ketan Kulkarni**

***Hodgkin's Lymphoma Update***

At the conclusion of this activity, participants will be able to:

1. Demonstrate the knowledge of new treatments for Hodgkin's Lymphoma.
2. Differentiate when the patient can be in the community versus IWK.
3. State the evidence for treatment of Hodgkin's Lymphoma.

**Provincial Meetings**

- Learning objectives TBD; registrants will contribute topics.

**Dr. Craig Erker**

***COG updates: Spring 2025***

At the conclusion of this activity, participants will be able to:

1. Discuss the Children's Oncology Group (COG).
2. Describe updates on clinical trial results.
3. Identify upcoming trials through COG.

**Saturday, May 3**

**Marjorie McGibbon, Misty Spencer, and Tonette Despres**

***Blinatumomab, part 1***

At the conclusion of this activity, participants will be able to:

1. Identify care requirements for Blinatumomab therapy provision in advanced center community hospitals specifically in NB.
2. State the constraints that come with rehomeing and providing this care in advanced center community hospitals.
3. Breakdown the successes demonstrated and what made this successful.
4. Summarize overall lessons learned from Moncton and how they can be applied to all advanced centre community hospitals.

**Dr. Joanne Delaney**

***Blinatumomab, part 2***

At the conclusion of this activity, participants will be able to:

1. Review the role of blinatumomab in upfront treatment of B-cell pediatric acute lymphoblastic leukemia.
2. Review common complications of blinatumomab and discuss management strategies.

**Discipline specific meetings**

- Learning objectives TBD; registrants will contribute topics.

**Sarah Keeping and Toni Leamon**

***Oncofertility***

At the conclusion of this activity, participants will be able to:

1. Identify the intended outcomes of the CPAC/APPHON oncofertility project for pediatric and young adult oncology patients and healthcare providers in Atlantic Canada.

2. Recognize the importance of timely fertility discussions and accurate documentation of these encounters.
3. State the role of provincial oncofertility guidelines and recommendations, including clinical care pathways, and how they can be utilized for evidence-based patient care.

**Erin Thorne**

***Pediatric Oncology Palliative Care in Atlantic Canada: A Needs Assessment***

At the conclusion of this presentation, participants will be able to:

1. Identify the key needs and challenges in delivering pediatric oncology palliative care across healthcare facilities in Atlantic Canada, as reported by healthcare providers.
2. Describe healthcare providers' perceptions and experiences regarding the integration of palliative care into pediatric oncology.
3. Discuss the findings of the survey responses and the preliminary results of focus group discussions on recommendations for optimizing delivery of pediatric palliative care in Atlantic Canada.

**Zara Forbrigger**

***The financial impact of pediatric cancer treatment to families treated at the IWK***

At the conclusion of this activity, participants will be able to:

1. Identify the out-of-pocket travel expenses families experienced travelling to the IWK for treatment.
2. Recognize the impact of these financial burdens on families.

**Brooke Dewhurst**

***Leukemia and Lymphoma Society of Canada***

At the conclusion of this activity, participants will be able to:

1. Describe the range of pediatric programs and services offered by the Leukemia and Lymphoma Society of Canada.
2. Recognize the various ways they can partner with the LLSC through referrals, continuing education, and upcoming events.

**Dr. Tamara MacDonald**

***Guidelines Update***

At the conclusion of this activity, participants will be able to:

- Review C. diff guidelines.
- Review immunization updates.

---

Agenda

---

**DAY ONE**

Thursday, May 1<sup>st</sup>

1200 Registration and light Lunch

1300 Welcome and Introductions  
1305 Hem/Onc Case Review – Dr. Lisa Goodyear  
1335 Discussion/Q&A  
1345 Chronic Transfusion Therapy – Jill Mitchell & Chantale Deyoung  
1420 Discussion/Q&A  
1430 Break  
1445 Non-Malignant Neutropenias – Dr. Valerie Bourque-Riel  
1520 Discussion/Q&A  
1530 Iron in the community – Dr. Lisa Pinto  
1605 Discussion/Q&A  
1615 Adjourn

## DAY TWO

Friday, May 2<sup>nd</sup>

0800 Registration and Coffee  
0830 Welcome  
0845 Cardio Oncology – Mary Stuart  
0908 Discussion/Q&A  
0915 Ethicist – Amanda Porter  
0950 Discussion/Q&A  
1000 Break  
1015 SSPedi: Symptom Screening in Pediatrics Tool – Dr. Lillian Sung, Guest Speaker  
1105 Discussion/Q&A  
1115 Precision Medicine in Pediatric Oncology: Expanding the Playing Field, or a Whole New Game? – Dr. Chelsea Ash  
1150 Discussion/Q&A  
1200 AGM – Carol Digout  
1215 Lunch  
1300 Hodgkin's Lymphoma Update – Dr. Ketan Kulkarni  
1335 Discussion/Q&A  
1345 Provincial Meetings (break served in rooms)  
1515 COG updates: Spring 2025 – Dr. Craig Erker  
1550 Discussion/Q&A  
1600 Adjourn

## DAY THREE

Saturday, May 3<sup>rd</sup>

0830 Coffee  
0900 Welcome

0915 Blinatumomab, part 1 – Christa Wheeler Thorne, Marjorie McGibbon, Misty Spencer and Tonette Despres  
0938 Discussion/Q&A  
0945 Blinatumomab, part 2 – Dr. Joanne Delaney  
1008 Discussion/Q&A  
1015 Discipline specific meetings (break served in rooms)  
1130 Oncofertility – Sarah Keeping and Toni Leamon  
1153 Discussion/Q&A  
1200 Lunch  
1245 Pediatric Oncology Palliative Care in Atlantic Canada: A Needs Assessment – Erin Thorne  
1308 Discussion/Q&A  
1315 Cost of Illness – Zara Forbrigger  
1338 Discussion/Q&A  
1345 Leukemia and Lymphoma Society of Canada – Brooke Dewhurst  
1356 Discussion/Q&A  
1400 Guidelines Update – Dr. Tamara MacDonald  
1435 Discussion/Q&A  
1445 Adjourn

---

### Scientific Planning Committee

---

Dr. Bruce Crooks  
Carol Digout  
Céline Richard  
Stephanie Eason  
Dr. Natacha Hébert  
Dr. Tamara MacDonald  
Marjorie McGibbon  
Christa McGuirk  
Jill Mitchell  
Holly Paynter

---

### Learning Objectives for the Conference

---

After attending this conference, participants should be informed about new guidelines, practices, literature, and treatment of patients with hematologic/oncologic diseases.

---

### Funding Sponsors

---

Pharmaceutical funding to be declared once confirmed.